Skip to main content

Table 4 Response to therapy

From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Response N (%)
Complete response 1 (4 %)
Partial response 4 (15 %)
Stable disease 11 (41 %)
Progressive disease 11 (41 %)